Home・Akcijų sąrašas・Genmab A-S

Genmab A-S

Uždarymo kaina

2,275 0.89

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2241

Max

2287

Pagrindiniai rodikliai
By Trading Economics
Pajamos	243M 295M
Pardavimai	259M 1.2B
P/E Sektoriaus vid.	26.002 56.432
Pelnas, tenkantis vienai akcijai	34.85
Pelno marža	25.541
Darbuotojai	3,119
EBITDA	216M 431M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-1.49% downside

Dividendai
By Acuity
Kitas uždarbis	2026-11-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	17B 130B
Ankstesnė atidarymo kaina	2274.11
Ankstesnė uždarymo kaina	2275

Genmab A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-18 23:56; UTC

Packaging Corp of America is trading modestly higher in after-market hours, despite unchanged U.S. industrial production and a decline in manufacturing output.

2026-09-18 23:56; UTC

Below 20-day average, near one-month range in after-market hours.

2026-09-18 23:55; UTC

Extreme Networks Inc is trading modestly higher in after-market hours, reflecting typical performance within its one-month range following Friday's close.

2026-09-18 23:55; UTC

Lumen Technologies Inc is trading modestly higher in after-market hours, rebounding from earlier lows amid a broader trend of five consecutive lower daily closes.

2026-09-18 23:55; UTC

Edison International is trading modestly higher in after-market hours, gradually advancing since Friday's close but remains below its 20-day moving average.

2026-09-18 23:52; UTC

Mosaic Co is trading modestly higher in after-hours activity, maintaining a position approximately 1.36% below its 20-day moving average.

2026-09-18 23:52; UTC

Grab Holdings Ltd is trading lower in after-market hours, reaching its lowest price of the day and remaining significantly below its 20-day moving average.

2026-09-18 23:52; UTC

Correlated Moves

Jabil Inc is advancing in after-market trading, reflecting a significant rise since Friday's close and aligning with gains in the iShares Dynamic Equity Active ETF.

2026-09-18 23:52; UTC

Generac Holdings Inc is seeing a modest increase in after-market trading, aligning with broader market trends despite stagnation in U.S. industrial production data for August.

2026-09-18 23:51; UTC

Pacific Biosciences of California Inc declined during after-market trading, moving lower since Friday's close and currently below its 20-day moving average.

2026-09-18 23:51; UTC

Ribbon Communications Inc is declining in after-market trading, moving lower since Friday's close and trading well below its 20-day moving average.

2026-09-18 23:51; UTC

Amphenol Corp is gaining in after-market trading, reaching a notable high since Friday's close, despite remaining below its 20-day moving average.

2026-09-18 23:51; UTC

Lincoln National Corp is trading modestly higher in after-market hours, influenced by broader market gains amid ongoing geopolitical tensions and mixed economic data.

2026-09-18 23:51; UTC

Kyndryl Holdings Inc is moving higher in after-market trading, supported by broader market trends, despite stagnation in U.S. industrial production data for August.

2026-09-18 23:51; UTC

Correlated Moves

Microchip Technology Inc. is trading modestly lower in after-market hours, following a decline from earlier gains amid a broader downturn in the semiconductor sector.

2026-09-18 23:51; UTC

Correlated Moves

Southern Copper Corp is trading modestly lower in after-market hours, continuing a trend observed throughout the day, amid stable performance from the NYLIM FTSE ETF.

2026-09-18 23:51; UTC

EHang Holdings Ltd shows notable strength in after-market trading, advancing significantly from earlier lows despite remaining near the lower end of its one-month trading range.

2026-09-18 23:51; UTC

Cleveland-Cliffs Inc declined in after-market trading but remains above its 20-day moving average and near the upper end of its one-month range.

2026-09-18 23:51; UTC

Charter Communications Inc is rising in after-market trading, reaching its highest cumulative return since Friday's close, reversing a trend of recent declines.

2026-09-18 23:51; UTC

Event

Paychex Inc is trading higher in after-market hours ahead of its Q1 FY2027 earnings report, with EPS estimated at $1.32 and revenue at $1.6 billion.

2026-09-18 23:51; UTC

Devon Energy Corp's shares are modestly higher during after-market hours, currently positioned around the middle of their one-month trading range.

2026-09-18 23:51; UTC

Correlated Moves

Pfizer Inc is trading lower in after-market hours, reflecting a decline since Friday's close, influenced by Bristol-Myers Squibb's recent performance.

2026-09-18 23:51; UTC

American Electric Power Company Inc is trading modestly higher in after-market hours, recovering from earlier lows but remains below its 20-day moving average.

2026-09-18 23:51; UTC

Tractor Supply Co is seeing a modest increase in after-market trading, recovering from an earlier dip amid stagnation in U.S. industrial production.

2026-09-18 23:51; UTC

Kinder Morgan Inc is declining in after-market trading, having reached its lowest point of the day after fluctuating sharply during the session.

2026-09-18 23:46; UTC

Lamb Weston Holdings Inc is trading modestly higher in after-market hours, recovering from a low point shortly after the market closed.

2026-09-18 23:46; UTC

BRC Group Holdings Inc is trading modestly higher in after-market hours, despite a notable decline from earlier gains during the session.

2026-09-18 23:46; UTC

Tripadvisor Inc's stock advanced in after-market trading, fluctuating between a low of 0.06% and a high of 1.19% since Friday's close.

2026-09-18 23:46; UTC

Correlated Moves

Portland General Electric Co is trading modestly higher in after-market hours, reflecting broader gains in the Electric Utilities sector alongside Alliant Energy Corp.

2026-09-18 23:46; UTC

Viavi Solutions Inc is seeing modest gains in after-market trading, recovering from earlier fluctuations that pulled the stock back from a session high.

Akcijų palyginimas

Kainos pokytis

Genmab A-S Prognozė

Kainos tikslas

By TipRanks

-1.49% į apačią

12 mėnesių prognozė

Vidutinis 2,493.35 DKK -1.49%

Aukščiausias 3,320 DKK

Žemiausias 308.417 DKK

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Genmab A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Genmab A-S akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.